Employer / Commercial Insurance
Covered with requirementsWhat you need to qualify
- Age 18 and older
- BMI of 30 or higher
- BMI of 27.5 or higher for patients of Asian descent
- 6 months of a documented diet and exercise program
- Diagnosed obstructive sleep apnea (AHI of 15 or higher), with a documented trial of PAP therapy
Qualification pathways
You can qualify through any one of these.
Initial approval for moderate to severe OSA
All of:
- Diagnosis of moderate to severe obstructive sleep apnea
- AHI/RDI/REI of at least 15 events per hour, predominantly obstructive
- Age 18 or older
- Actively enrolled in an exercise and caloric reduction program
- Not using Zepbound concurrently with a GLP-1 receptor agonist
Plus any one of:
- BMI >= 30 kg/m2
- Asian patient with BMI >= 27.5 kg/m2
Initial OSA approval — PAP therapy condition
All of:
- All other OSA initial criteria met
Plus any one of:
- Persistent OSA symptoms despite PAP adherence (at least 4 hours per night on at least 70% of nights)
- Clinical documentation that patient is not a candidate for PAP
- Clinical documentation that patient is intolerant of PAP
Documentation to bring
- Documentation of moderate to severe OSA diagnosis
- AHI/RDI/REI result showing >= 15 events per hour that is predominantly obstructive
- Documentation of BMI >= 30 kg/m2 (or >= 27.5 kg/m2 for Asian patients)
- Documentation of active enrollment in exercise and caloric reduction program
- Documentation of persistent OSA symptoms despite PAP adherence (>=4 hours/night on >=70% of nights) OR clinical documentation of ineligibility or intolerance to PAP
- Confirmation that Zepbound will not be used concurrently with a GLP-1 receptor agonist
Approval and renewal
- To renew, the plan looks for Patient must have achieved or maintained a reduction in AHI/RDI/REI by at least 15 events per hour OR by at least 50%. Concurrent GLP-1 receptor agonist use remains prohibited at renewal.
Not covered when
- Concurrent use of a GLP-1 receptor agonist (liraglutide, semaglutide, exenatide, exenatide extended-release)
Policy note: OSA must be predominantly obstructive. PAP adherence is defined as at least 4 hours per night on at least 70% of nights. At renewal, AHI/RDI/REI must be reduced by at least 15 events per hour OR by at least 50% from baseline. Age and lifestyle program enrollment requirements from initial criteria are not explicitly re-verified at renewal per the renewal criteria text; only the AHI/RDI/REI improvement and no concurrent GLP-1 use are listed as renewal requirements.
Policy effective June 1, 2026 · verified June 5, 2026 · source: Standard-Commercial-Guidelines-6-1-26-EXCERPTED.pdf